Home » Stocks » Inventiva

Inventiva SA (IVA)

Stock Price: $13.76 USD -0.74 (-5.10%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 528.09M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 38.38M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $13.76
Previous Close $14.50
Change ($) -0.74
Change (%) -5.10%
Day's Open 13.92
Day's Range 13.57 - 14.50
Day's Volume 6,679
52-Week Range 9.01 - 15.95

More Stats

Market Cap 528.09M
Enterprise Value 485.84M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.38M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 158,383
Short Ratio 6.40
Short % of Float n/a
Beta 1.14
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 11.25
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 42.25M
Net Cash / Share 1.10
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -24.39%
ROE -60.79%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(103.49% upside)
Current: $13.76
Target: 28.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth53.02%-
Gross Profit11.297.38
Operating Income-30.31-32.90
Net Income-30.22-33.01
Shares Outstanding23.5220.54
Earnings Per Share-1.28-1.61
Operating Cash Flow-28.40-34.21
Capital Expenditures-0.13-0.55
Free Cash Flow-28.54-34.76
Cash & Equivalents35.8456.69
Total Debt0.120.23
Net Cash / Debt35.7356.47
Book Value41.3961.60
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Inventiva SA
Country France
Employees 86
CEO Frédéric Cren

Stock Information

Ticker Symbol IVA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IVA
IPO Date July 10, 2020


Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.